A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
- Status
- COMPLETED
- Phase
- PHASE2
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Status
- RECRUITING
- Phase
- PHASE2
Neo-NTP-CRT for Locally Advanced ESCC
- Status
- UNKNOWN
- Phase
- PHASE2
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
- Status
- TERMINATED
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Status
- TERMINATED
- Phase
- PHASE3
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1